Table 3.
Univariate Analysis of Prognostic Factors for DSS in the Gynecological and Nongynecological LMS
| Factors | Gynecological LMS (76)
|
P | Nongynecological LMS (73)
|
P |
|---|---|---|---|---|
| 5DSS Rate % (number of cases) | 5DSS Rate % (number of cases) | |||
| Age | ||||
| <50 | 53 (36) | NS (0.8) | 61 (29) | NS (0.8) |
| ≥50 | 56 (40) | 64 (44) | ||
| Tumor size | ||||
| ≤10 cm | 71 (44) | 0.03 | 73 (45) | 0.02 |
| >10 cm | 33 (25) | 44 (24) | ||
| Histological grade* | ||||
| 1 | 37 (20) | NS (0.9) | 83 (19) | NS (0.15) |
| 2 | 62 (38) | 66 (34) | ||
| 3 | 59 (18) | 40 (12) | ||
| Mitotic index | ||||
| 1 | 62 (23) | 0.003 | 82 (24) | NS (0.3) |
| 2 | 95 (21) | 63 (24) | ||
| 3 | 33 (32) | 53 (17) | ||
| Necrosis | ||||
| 0 | 53 (45) | NS (0.7) | 68 (43) | NS (0.7) |
| 1 | 55 (26) | 55 (16) | ||
| 2 | 66 (5) | 75 (6) | ||
| CSF1 signature† | ||||
| Positive | 0 (14) | 6 × 10−5 | 53 (28) | 0.03 |
| Negative | 58 (50) | 74 (35) |
*
FNCLCC grading system was used to classify nongynecological LMS. We classified the gynecological LMS based on cellular differentiation.
†
LMS that co-expressed all four markers (CSF1, CTSL1, FCGR3a, and CD163) were considered CSF1 signature-positive. LMS that failed to express at least one or more of the four markers were called CSF1 signature-negative.
5DSS, 5-year disease-specific survival rate in percentage (number of cases); NS, not statistically significant.